MedTrace Logo

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

NCT07384429 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-03-23

No results posted yet for this study

Summary

The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.

Conditions

Interventions

DRUG

Lemborexant

Participants will receive oral Lemborexant (5 mg/day) nightly approximately 5-30 minutes before going to bed for 28 consecutive days.

DRUG

placebo

Participants will receive a matching placebo nightly approximately 5-30 minutes before going to bed for 28 consecutive days.

Sponsors & Collaborators

  • Eisai China Inc.

    collaborator INDUSTRY

  • Nanjing University

    collaborator OTHER

  • YangPan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-19
Primary Completion
2026-12-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07384429 on ClinicalTrials.gov